Suspension of trading

Income Statement Deciphera Pharmaceuticals, Inc.

Stocks

DCPH

US24344T1016

Biotechnology & Medical Research

Delayed Nasdaq 16:00:00 2024-06-10 EDT			5-day change	1st Jan Change
25.59 ^USD	+0.08%		-.--%	-

06-17	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
03-26	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI

a45b482d2440efd55853c53b8c.uaMqi9U3Hoe7zTuGZB7tzZUzKlh4QqQwjkzYj_H9z8w.8edd6p0OasaD_VjAF32qivdDXCsfNc9FuD-pwIHL_7velEmzmmQm6u2CWA

Published financial data: DECIPHERA PHARMACEUTICALS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Revenues	25M	42.09M	96.15M	134M	163M
Total Revenues	25M	42.09M	96.15M	134M	163M
Cost of Goods Sold, Total	-	199M	238M	197M	238M
Gross Profit	25M	-157M	-142M	-62.56M	-74.5M
Selling General & Admin Expenses, Total	65.72M	114M	132M	120M	136M
R&D Expenses	158M	-	-	-	-
Other Operating Expenses, Total	223M	114M	132M	120M	136M
Operating Income	-198M	-271M	-274M	-183M	-211M
Interest Expense, Total	-67K	-	-	-	-
Interest And Investment Income	8.54M	4.7M	113K	4.51M	16.45M
Net Interest Expenses	8.47M	4.7M	113K	4.51M	16.45M
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	-190M	-266M	-274M	-178M	-195M
Restructuring Charges	-	-	-26.2M	-	-
Other Unusual Items	-2.4M	-	-	-	-
EBT, Incl. Unusual Items	-192M	-266M	-300M	-178M	-195M
Income Tax Expense	-	-	-	722K	431K
Earnings From Continuing Operations	-192M	-266M	-300M	-179M	-195M
Net Income to Company	-192M	-266M	-300M	-179M	-195M
Net Income - (IS)	-192M	-266M	-300M	-179M	-195M
Net Income to Common Incl Extra Items	-192M	-266M	-300M	-179M	-195M
Net Income to Common Excl. Extra Items	-192M	-266M	-300M	-179M	-195M
Per Share Items
Net EPS - Basic	-4.48	-4.78	-5.16	-2.37	-2.29
Basic EPS - Continuing Operations	-4.48	-4.78	-5.16	-2.37	-2.29
Basic Weighted Average Shares Outstanding	42.87M	55.78M	58.08M	75.5M	85.06M
Net EPS - Diluted	-4.48	-4.78	-5.16	-2.37	-2.29
Diluted EPS - Continuing Operations	-4.48	-4.78	-5.16	-2.37	-2.29
Diluted Weighted Average Shares Outstanding	42.87M	55.78M	58.08M	75.5M	85.06M
Normalized Basic EPS	-2.77	-2.99	-2.95	-1.48	-1.43
Normalized Diluted EPS	-2.77	-2.99	-2.95	-1.48	-1.43
Supplemental Items
EBITDA	-197M	-269M	-271M	-180M	-209M
EBITA	-198M	-271M	-274M	-183M	-211M
EBIT	-198M	-271M	-274M	-183M	-211M
EBITDAR	-195M	-264M	-264M	-174M	-204M
Total Revenues (As Reported)	-	42.09M	96.15M	134M	163M
Effective Tax Rate - (Ratio)	-	-	-	-0.41	-0.22
Current Foreign Taxes	-	-	-	-	431K
Total Current Taxes	-	-	-	-	431K
Normalized Net Income	-119M	-167M	-171M	-111M	-122M
Interest on Long-Term Debt	100K	-	-	-	-
Supplemental Operating Expense Items
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	158M	199M	257M	188M	234M
Net Rental Expense, Total	2.17M	4.98M	6.76M	6M	4.88M
Imputed Operating Lease Interest Expense	123K	-	-	-	-
Imputed Operating Lease Depreciation	2.05M	-	-	-	-
Stock-Based Comp., COGS (Total)	-	17.44M	20.7M	22.24M	21.78M
Stock-Based Comp., R&D Exp. (Total)	7.93M	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	12.48M	19.69M	25.38M	29.7M	28.83M
Total Stock-Based Compensation	20.41M	37.14M	46.08M	51.94M	50.6M

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Assets
Cash And Equivalents	120M	136M	87.06M	64.74M	83.51M
Short Term Investments	459M	416M	199M	260M	223M
Total Cash And Short Term Investments	580M	552M	286M	324M	306M
Accounts Receivable, Total	-	13.9M	20.6M	22.43M	31.95M
Total Receivables	-	13.9M	20.6M	22.43M	31.95M
Inventory	-	5.72M	14.12M	20.56M	21.21M
Prepaid Expenses	13.83M	12.49M	18.66M	25.48M	21.72M
Total Current Assets	593M	584M	339M	393M	381M
Gross Property Plant And Equipment	29.32M	50.05M	52.55M	53.34M	49.69M
Accumulated Depreciation	-1.83M	-4.12M	-7.14M	-10.08M	-12.2M
Net Property Plant And Equipment	27.49M	45.92M	45.41M	43.25M	37.49M
Long-term Investments	-	9.38M	41.95M	14.55M	46.7M
Deferred Charges Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	1.51M	3.1M	3.11M	3.28M	8.28M
Total Assets	622M	642M	429M	454M	474M
Liabilities
Accounts Payable, Total	19.58M	12.31M	13.13M	18.61M	26.48M
Accrued Expenses, Total	37.17M	51.82M	50.19M	43.66M	42.28M
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	1.75M	2.46M	2.87M	3.24M	3.5M
Other Current Liabilities	1.54M	3.41M	30.58M	20.96M	28.01M
Total Current Liabilities	60.04M	69.99M	96.77M	86.47M	100M
Long-Term Debt	-	-	-	-	-
Long-Term Leases	15.9M	28.76M	27.99M	25.88M	22.38M
Other Non Current Liabilities	-	-	-	-	-
Total Liabilities	75.94M	98.76M	125M	112M	123M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	516K	576K	585K	676K	805K
Additional Paid In Capital	1.03B	1.3B	1.36B	1.58B	1.78B
Retained Earnings	-488M	-754M	-1.05B	-1.23B	-1.43B
Comprehensive Income and Other	111K	11K	51K	-983K	577K
Total Common Equity	546M	544M	305M	342M	351M
Total Equity	546M	544M	305M	342M	351M
Total Liabilities And Equity	622M	642M	429M	454M	474M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	55.65M	57.63M	58.55M	75.95M	80.8M
ECS Total Common Shares Outstanding	51.62M	57.6M	57.6M	67.64M	80.5M
Book Value / Share	10.59	9.44	5.29	5.05	4.36
Tangible Book Value	546M	544M	305M	342M	351M
Tangible Book Value Per Share	10.59	9.44	5.29	5.05	4.36
Total Debt	17.65M	31.22M	30.86M	29.11M	25.88M
Net Debt	-562M	-530M	-297M	-310M	-327M
Debt Equivalent Oper. Leases	17.36M	39.86M	54.08M	47.97M	39.07M
Account Code - Inventory Valuation	3	5	5	5	5
Inventories - Raw Materials, Total	-	1.35M	4.72M	6.84M	-
Inventories - Work In Process, Total	-	4.14M	7.92M	11.12M	-
Inventories - Finished Goods, Total	-	222K	1.48M	2.59M	-
Machinery, Total	7.09M	11.61M	13.56M	14.45M	15.47M
Full Time Employees	255	350	280	300	355
Part Time Employees	3	-	-	-	-

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Net Income	-192M	-266M	-300M	-179M	-195M
Depreciation & Amortization - CF	830K	2.3M	3.01M	2.95M	2.1M
Depreciation & Amortization, Total	830K	2.3M	3.01M	2.95M	2.1M
(Gain) Loss From Sale Of Asset	-	-7K	-	-	-
(Gain) Loss on Sale of Investments - (CF)	-4M	-1.61M	1.78M	-1.3M	-7.4M
Asset Writedown & Restructuring Costs	-	-	4M	-	-
Stock-Based Compensation (CF)	20.41M	37.14M	46.08M	51.94M	50.6M
Other Operating Activities, Total	-	2.83M	3.45M	4.13M	4.48M
Change In Accounts Receivable	-	-13.9M	-6.7M	-1.78M	-9.34M
Change In Inventories	-	-3.24M	-10.16M	-7.11M	-386K
Change In Accounts Payable	10.86M	-7.53M	833K	5.32M	7.78M
Change In Income Taxes	-	-	-	722K	431K
Change in Other Net Operating Assets	14.86M	10.82M	16.84M	-28.8M	-13K
Cash from Operations	-149M	-240M	-241M	-153M	-147M
Capital Expenditure	-4.94M	-5.32M	-1.97M	-841K	-778K
Sale of Property, Plant, and Equipment	-	7K	-	-	-
Sale (Purchase) of Intangible assets	-	-	-4M	-	-
Investment in Marketable and Equity Securities, Total	-455M	35.36M	183M	-33.47M	13.33M
Other Investing Activities, Total	-441K	-1.59M	-7K	-	-
Cash from Investing	-461M	28.46M	177M	-34.31M	12.55M
Long-Term Debt Issued, Total	-	-	-	-	-
Total Debt Issued	-	-	-	-	-
Long-Term Debt Repaid, Total	-1.29M	-	-	-	-
Total Debt Repaid	-1.29M	-	-	-	-
Issuance of Common Stock	438M	228M	14.93M	165M	153M
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-620K	-815K	-40K	-425K	-634K
Cash from Financing	436M	227M	14.89M	165M	152M
Foreign Exchange Rate Adjustments	-	-	252K	-145K	910K
Net Change in Cash	-173M	15.58M	-48.83M	-22.32M	18.77M
Supplemental Items
Cash Interest Paid	67K	-	-	-	-
Levered Free Cash Flow	-78.51M	-144M	-123M	-85.92M	-72.79M
Unlevered Free Cash Flow	-78.47M	-144M	-123M	-85.92M	-72.79M
Change In Net Working Capital	-29.18M	9.02M	-5.09M	25.76M	-7.13M
Net Debt Issued / Repaid	-1.29M	-	-	-	-

Fiscal Period: December	2019 (USD)	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)
Profitability
Return on Assets	-26.43	-26.8	-31.94	-25.85	-28.43
Return on Total Capital	-29.32	-29.76	-37.6	-32.33	-35.27
Return On Equity %	-46.53	-48.89	-70.71	-55.36	-56.29
Return on Common Equity	-46.53	-48.89	-70.71	-55.36	-56.29
Margin Analysis
Gross Profit Margin %	100	-373.29	-147.3	-46.67	-45.61
SG&A Margin	262.86	271.06	137.55	89.65	83.53
EBITDA Margin %	-789.98	-638.88	-281.71	-134.13	-127.85
EBITA Margin %	-793.3	-644.36	-284.85	-136.32	-129.14
EBIT Margin %	-793.3	-644.36	-284.85	-136.32	-129.14
Income From Continuing Operations Margin %	-769.02	-633.19	-311.98	-133.49	-119.34
Net Income Margin %	-769.02	-633.19	-311.98	-133.49	-119.34
Net Avail. For Common Margin %	-769.02	-633.19	-311.98	-133.49	-119.34
Normalized Net Income Margin	-474.64	-395.74	-177.96	-83.1	-74.42
Levered Free Cash Flow Margin	-314.06	-343.08	-127.89	-64.1	-44.56
Unlevered Free Cash Flow Margin	-313.89	-343.08	-127.89	-64.1	-44.56
Asset Turnover
Asset Turnover	0.05	0.07	0.18	0.3	0.35
Fixed Assets Turnover	1.22	1.15	2.11	3.02	4.05
Receivables Turnover (Average Receivables)	-	-	5.58	6.23	6.01
Inventory Turnover (Average Inventory)	-	-	23.97	11.34	11.39
Short Term Liquidity
Current Ratio	9.88	8.34	3.5	4.54	3.8
Quick Ratio	9.65	8.08	3.16	4.01	3.37
Operating Cash Flow to Current Liabilities	-2.49	-3.42	-2.49	-1.77	-1.46
Days Sales Outstanding (Average Receivables)	-	-	65.47	58.58	60.75
Days Outstanding Inventory (Average Inventory)	-	-	15.23	32.2	32.05
Average Days Payable Outstanding	-	-	18.86	28.53	34.5
Cash Conversion Cycle (Average Days)	-	-	61.84	62.25	58.3
Long Term Solvency
Total Debt/Equity	3.23	5.74	10.13	8.52	7.37
Total Debt / Total Capital	3.13	5.43	9.2	7.85	6.87
LT Debt/Equity	2.91	5.29	9.19	7.57	6.38
Long-Term Debt / Total Capital	2.82	5	8.34	6.98	5.94
Total Liabilities / Total Assets	12.2	15.37	29.05	24.74	25.9
EBIT / Interest Expense	-2.96K	-	-	-	-
EBITDA / Interest Expense	-2.92K	-	-	-	-
(EBITDA - Capex) / Interest Expense	-2.99K	-	-	-	-
Total Debt / EBITDA	-0.09	-0.12	-0.12	-0.17	-0.13
Net Debt / EBITDA	2.88	2.01	1.12	1.78	1.6
Total Debt / (EBITDA - Capex)	-0.09	-0.12	-0.12	-0.17	-0.13
Net Debt / (EBITDA - Capex)	2.81	1.97	1.12	1.77	1.6
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-	68.35	128.45	39.41	21.87
Gross Profit, 1 Yr. Growth %	-	18.47	-9.86	-55.83	19.09
EBITDA, 1 Yr. Growth %	90.3	36.15	0.74	-33.63	16.18
EBITA, 1 Yr. Growth %	90.52	36.74	0.99	-33.28	15.45
EBIT, 1 Yr. Growth %	90.52	36.74	0.99	-33.28	15.45
Earnings From Cont. Operations, 1 Yr. Growth %	92.54	38.61	12.56	-40.35	8.95
Net Income, 1 Yr. Growth %	92.54	38.61	12.56	-40.35	8.95
Normalized Net Income, 1 Yr. Growth %	90.13	40.36	2.73	-34.9	9.15
Diluted EPS Before Extra, 1 Yr. Growth %	58.95	6.53	8.1	-54.11	-3.3
Accounts Receivable, 1 Yr. Growth %	-	-	48.21	8.9	42.46
Inventory, 1 Yr. Growth %	-	-	147.11	45.56	3.16
Net Property, Plant and Equip., 1 Yr. Growth %	104.35	67.05	-1.12	-4.75	-13.32
Total Assets, 1 Yr. Growth %	97.24	3.22	-33.15	5.72	4.3
Tangible Book Value, 1 Yr. Growth %	95.18	-0.51	-43.95	12.13	2.7
Common Equity, 1 Yr. Growth %	95.18	-0.51	-43.95	12.13	2.7
Cash From Operations, 1 Yr. Growth %	72.03	60.54	0.48	-36.53	-4.03
Capital Expenditures, 1 Yr. Growth %	338.67	7.72	-62.94	-57.31	-7.49
Levered Free Cash Flow, 1 Yr. Growth %	47.72	83.91	-14.84	-30.13	-15.27
Unlevered Free Cash Flow, 1 Yr. Growth %	47.79	84	-14.84	-30.13	-15.27
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-	-	96.11	78.46	30.35
Gross Profit, 2 Yr. CAGR %	-	37.68	3.34	-36.9	-27.47
EBITDA, 2 Yr. CAGR %	97.2	60.96	17.11	-18.23	-12.19
EBITA, 2 Yr. CAGR %	97.32	61.4	17.51	-17.92	-12.24
EBIT, 2 Yr. CAGR %	97.32	61.4	17.51	-17.92	-12.24
Earnings From Cont. Operations, 2 Yr. CAGR %	95.54	63.36	24.91	-18.06	-19.38
Net Income, 2 Yr. CAGR %	95.54	63.36	24.91	-18.06	-19.38
Normalized Net Income, 2 Yr. CAGR %	94.31	63.36	20.08	-18.22	-15.71
Diluted EPS Before Extra, 2 Yr. CAGR %	22.38	30.12	7.31	-29.57	-33.38
Accounts Receivable, 2 Yr. CAGR %	-	-	-	27.05	24.56
Inventory, 2 Yr. CAGR %	-	-	-	89.66	22.54
Net Property, Plant and Equip., 2 Yr. CAGR %	472.76	84.76	28.52	-2.95	-9.13
Total Assets, 2 Yr. CAGR %	76.81	42.68	-16.93	-15.93	5.01
Tangible Book Value, 2 Yr. CAGR %	72.35	39.35	-25.33	-20.72	7.31
Common Equity, 2 Yr. CAGR %	72.35	39.35	-25.33	-20.72	7.31
Cash From Operations, 2 Yr. CAGR %	101.69	66.19	27.01	-20.14	-21.95
Capital Expenditures, 2 Yr. CAGR %	248.64	117.38	-36.82	-60.23	-37.16
Levered Free Cash Flow, 2 Yr. CAGR %	105.11	64.82	25.14	-22.86	-23.06
Unlevered Free Cash Flow, 2 Yr. CAGR %	105.38	64.9	25.18	-22.86	-23.06
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	-	-	75.02	57.16
Gross Profit, 3 Yr. CAGR %	-	-	19.55	-22.16	-22.02
EBITDA, 3 Yr. CAGR %	97.21	74.29	37.68	-3.08	-8.08
EBITA, 3 Yr. CAGR %	97.26	74.62	38.05	-2.69	-8.03
EBIT, 3 Yr. CAGR %	97.26	74.62	38.05	-2.69	-8.03
Earnings From Cont. Operations, 3 Yr. CAGR %	94.97	74.35	44.29	-2.37	-9.9
Net Income, 3 Yr. CAGR %	94.97	74.35	44.29	-2.37	-9.9
Normalized Net Income, 3 Yr. CAGR %	94.16	74.35	39.96	-2.09	-9.96
Diluted EPS Before Extra, 3 Yr. CAGR %	26.2	16.85	22.32	-19.15	-21.72
Accounts Receivable, 3 Yr. CAGR %	-	-	-	-	31.99
Inventory, 3 Yr. CAGR %	-	-	-	-	54.82
Net Property, Plant and Equip., 3 Yr. CAGR %	276.77	279.84	50.01	16.31	-6.54
Total Assets, 3 Yr. CAGR %	119.39	47.77	10.82	-9.98	-9.67
Tangible Book Value, 3 Yr. CAGR %	57.54	43.5	2.86	-14.49	-13.58
Common Equity, 3 Yr. CAGR %	57.54	43.5	2.86	-14.49	-13.58
Cash From Operations, 3 Yr. CAGR %	86.3	86.92	40.53	0.79	-15.1
Capital Expenditures, 3 Yr. CAGR %	180.76	135.7	20.53	-44.56	-47.3
Levered Free Cash Flow, 3 Yr. CAGR %	79.66	97.78	32.26	3.05	-20.41
Unlevered Free Cash Flow, 3 Yr. CAGR %	79.92	97.99	32.3	3.07	-20.41
Compound Annual Growth Rate Over Five Years
Gross Profit, 5 Yr. CAGR %	-	-	-	-	-2.11
EBITDA, 5 Yr. CAGR %	-	72.63	60.1	28.77	15.01
EBITA, 5 Yr. CAGR %	-	72.78	60.35	29.11	15.17
EBIT, 5 Yr. CAGR %	-	72.78	60.35	29.11	15.17
Earnings From Cont. Operations, 5 Yr. CAGR %	-	68.16	63.16	28.9	14.32
Net Income, 5 Yr. CAGR %	-	68.16	63.16	28.9	14.32
Normalized Net Income, 5 Yr. CAGR %	-	68.16	60.21	28.8	14.27
Diluted EPS Before Extra, 5 Yr. CAGR %	-	0.47	18.28	-4.57	-4.07
Net Property, Plant and Equip., 5 Yr. CAGR %	-	159.94	145.04	120.07	22.75
Total Assets, 5 Yr. CAGR %	-	88.79	48.76	17.93	8.46
Tangible Book Value, 5 Yr. CAGR %	-	36.36	16.87	13.18	4.62
Common Equity, 5 Yr. CAGR %	-	36.36	16.87	13.18	4.62
Cash From Operations, 5 Yr. CAGR %	-	78.39	59.83	33.02	11.07
Capital Expenditures, 5 Yr. CAGR %	-	106.38	54.61	15.68	-7.11
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	55.47	35.71	6.49
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	55.62	35.8	6.51